Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):885-92. doi: 10.1517/17425255.2014.907794. Epub 2014 Apr 9.

Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder.

Author information

  • 1University of Milan, Department of Psychiatry, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico , Milan , Italy massimiliano.buoli@hotmail.it.

Abstract

INTRODUCTION:

Preliminary data indicate agomelatine as a promising molecule for both acute and long-term treatment of generalised anxiety disorder (GAD).

AREAS COVERED:

The present review illustrates the pharmacokinetic properties of agomelatine and their implications for the management of GAD patients. A search of the main database sources (Medline, Isi Web of Knowledge and Medscape) was performed in order to obtain a complete and balanced evaluation of agomelatine pharmacokinetics for the treatment of GAD. The word 'agomelatine' was associated with 'pharmacokinetics', 'GAD', 'anxiety' and 'tolerability'. No restriction criteria were established in relation to methodology or year of publication. Only English-language articles were included.

EXPERT OPINION:

Short half-life and 1-day administration make agomelatine an interesting molecule for GAD treatment. However, potential interactions with a number of compounds necessitate caution when prescribing and using agomelatine in patients with psychiatric (e.g., alcohol abuse) or medical comorbidities. Further data are necessary to define a precise risk/benefit ratio in special populations such as elderly patients suffering from GAD.

KEYWORDS:

agomelatine; generalised anxiety disorder; pharmacokinetics

PMID:
24717138
[PubMed - in process]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk